Quantcast

Latest Biologic Stories

2014-08-05 08:35:59

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growthhttp://www.reportbuyer.com/pharma_healthcare/treatments/systemic_psoriasis_therapeutics_major_developed_markets_2020_continued_uptake_biologics_novel_pipeline_drugs_drive_growth.htmlSystemic Psoriasis Therapeutics in Major Developed Markets to 2020 -...

2014-08-05 08:32:23

-- Executed Agreement with Evonik for Formulation Development, Analytical Services andClinical Drug Manufacturing -- ROCKVILLE, Md., Aug. 5, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today announced that, with a new multi-service agreement in place, the Company is on track to initiate Phase Ia and Ib clinical trials of...

2014-07-31 08:34:53

-- Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition -- ROCKVILLE, Md., July 31, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating...

2014-07-30 12:30:51

Step Edits Are the Most Likely Strategy to Drive Use of a Biosimilar Priced 30 Percent Less than the Reference Brand, According to Findings from Decision Resources Group BURLINGTON, Mass., July 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed pharmacy and medical directors in the United States believe that the key drivers of biosimilar market penetration will be the level of savings achievable by their managed care organizations (MCOs) and the expected...

2014-07-29 23:07:36

MarketOptimizer.org adds “PharmaSphere Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market” to its store. The report discusses the various regulatory frameworks under which biosimilars are currently reviewed and regulated. Dallas, Texas (PRWEB) July 29, 2014 PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market report is an essential source of information and analysis on the global biosimilars industry. Using detailed...

2014-07-29 12:36:03

ROCKVILLE, Md., July 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange") has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity....

2014-07-29 08:32:40

BEIJING, July 29, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release second quarter 2014 financial results on Tuesday, August 5, 2014 after the market closes. The Company's management will hold a conference call at 8:00 a.m. ET on Wednesday, August 6, 2014, which is 8:00 p.m., Beijing Time on August 6,...

2014-07-24 12:25:16

CARLSBAD, Calif., July 24, 2014 /PRNewswire/ -- Advanced Biologics, currently attending the NASS Summer Spine Meeting in Amelia Island, FL, announced today the publishing of two abstracts within The Bone and Joint Journal. Initially presented at the European Orthopaedic Research Society meeting, both abstracts further substantiate the differentiation and clinical benefit of OsteoAMP® allograft-derived growth factor. The first abstract, "Osteoinductivity and osteogenicity of...

2014-07-23 12:31:16

Study quantifies lost savings from REMS and related restricted access tactics WASHINGTON, July 23, 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies (REMS) and other restricted access programs to delay generic market entry results in $5.4 billion in lost savings annually, according to a new survey and analysis by economic consulting firm Matrix Global Advisors (MGA). Logo - http://photos.prnewswire.com/prnh/20140723/129680 Required by the Food and Drug...

2014-07-23 08:30:59

MARIETTA, Ga., July 23, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has filed its initial Investigational New Drug ("IND") application with the Food and Drug Administration ("FDA"). The IND submission, which was filed yesterday, July 22, 2014, is the Company's initial submission for certain indications...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related